• Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • About
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Advertise
PharmaLive
  • Marketing & Advertising
  • R&D
  • Therapeutics
  • Resources
  • Manny Awards
  • Events
  • Issue Archives
  • Subscribe
  • Search
  • Menu

Provention Bio and Johnson & Johnson Ink Deal

Anti-colony-stimulating factor 1 receptor (CSF1R) antibodies, Anti-Toll-Like Receptor 3 (TLR3) monoclonal antibody, Business, Crohn's Disease, Deals, Immune-Mediated Diseases, Influenza, Irritable Bowel Syndrome, Ulcerative Colitis (UC), Vaccines, Viral Diseases

Provention Bio agreed to in-license two clinical-stage assets for immune-mediated diseases from Janssen Pharmaceutica and Janssen Sciences Ireland.

Read more
September 21, 2017/by BioSpace
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2017-09-21 05:59:102017-09-21 13:34:04Provention Bio and Johnson & Johnson Ink Deal
Recent
  • Anne Maria Robertson, EversanaTaking oncology therapies to market requires change in commercialization...January 26, 2023 - 10:08 am
  • amoxicillinEU drug regulator decides ongoing antibiotic shortage not...January 26, 2023 - 9:38 am
  • Hand, doctor, stopPatient death pauses another AML trialJanuary 26, 2023 - 9:32 am
  • WalgreensWalgreens weighs $2 bln sale of pharmacy automation unit...January 26, 2023 - 7:09 am
Popular
  • Anne Maria Robertson, EversanaTaking oncology therapies to market requires change in commercialization...January 26, 2023 - 10:08 am
  • M&A, Partnerships And CollaborationsJanuary 1, 2011 - 1:48 pm
  • OTC Review And OutlookMarch 9, 2011 - 4:17 pm
  • Global Contract Manufacturing Companies: Pharmaceutical...November 11, 2011 - 3:31 pm
Tags
AbbVie acquisition Alzheimer's disease AstraZeneca Biogen BioNTech Bristol-Myers Squibb cancer China clinical trial clinical trials Covid-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines Data Eli Lilly European Union FDA featured GSK healthcare communications Healthcare Communications Agencies healthcare marketing Johnson & Johnson Moderna monkeypox monkeypox vaccine Novartis omicron Oncology pandemic Paxlovid people on the move Pfizer rare disease regulatory approval Roche Sanofi U.S. Centers for Disease Control and Prevention (CDC) U.S. Food and Drug Administration (FDA) United States Vaccines World Health Organization zoonotic diseases
© Copyright - PharmaLive and Outcomes LLC | Designed by Joe Lumi LLC
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
Scroll to top